Replimune Group Inc.

(NASDAQ:REPL) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Replimune Group Inc is a clinical-stage biotechnology company. Its use proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. The company's pipeline products include RP1, RP2, and RP3.

Contact Information

Website: www.replimune.com
Email: ir@replimune.com
Main Phone: +1 781 222-9600
Address: 500 Unicorn Park
State: MA
City / Town: Woburn
Country: US
Postal Code: 01801

Issuer Information

Exchange: NGS
CEO: Philip Astley-Sparke
Employees: 122
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A